SBI Mutual Fund increased its stake in Biocon Limited from 8.75% to 9.18%, purchasing 69,68,515 shares.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
India's largest AMC by total AUM, managing over Rs 11 lakh crore across equity, debt and hybrid schemes. Backed by State Bank of India, the country's largest bank, which gives it unmatched retail reach across every Indian state. With over 70 schemes and 50 million folios, SBI MF's positioning moves are tracked as a proxy for domestic institutional flows.
